VRAX (Virax Biolabs Group) GF Value Rank: 8 (As of Jul. 31, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
45 GF Score
Price $2.63
GF Value $3.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group GF Value Rank?

Virax Biolabs Group VRAX -5.90% 45 GF Value Rank is 8 as of Jul. 31, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates VRAX with a GF Score™ of 45/100 and a GF Value™ of $3.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Virax Biolabs Group has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Virax Biolabs Group GF Value Rank Related Terms


VRAX vs ISCO, PKTX, GRI: GF Value Rank Comparison

For the Biotechnology subindustry, Virax Biolabs Group's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's GF Value Rank falls into.


VRAX
45GF Score
Virax Biolabs Group Ltd VRAX
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
Virax Biolabs Group (VRAX) has a GF Value Rank of 8 as of Jul. 31, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Virax Biolabs Group and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Virax Biolabs Group's GF Value Rank has ranged from 4.00 to 4.00.
Is Virax Biolabs Group's GF Value Rank too high?
Virax Biolabs Group's current GF Value Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 4.00. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's GF Value Rank compare to ISCO and PKTX?
Virax Biolabs Group's GF Value Rank of 8 can be compared against companies in the Biotechnology industry. Historically, Virax Biolabs Group's own GF Value Rank has ranged from 4.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current GF Value Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.61, compared to a current price of $2.63 — trading 27.1% below its estimated fair value. The current GF Value Rank is 8, which is 100% above median its 10-year median of 4.00. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current GF Value Rank is 8 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued. The current stock price of $2.63 is trading 27.1% below its estimated GF Value™ of $3.61. GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.

Key valuation signals for VRAX:

  • GF Value Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: $3.61 vs. price of $2.63 (27.1% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score

Get the complete analysis for VRAX

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63
Price
$3.61
GF Value